Autoimmune Hemolytic Anemia Therapeutics Market 2024-2028: Size and Lack of effective therapies; growth driven by the Product, Some of key Companies Positioned Strategically

The autoimmune hemolytic anemia therapeutics market size by Product (Corticosteroids, Monoclonal antibodies, and Others) and Geography (North America, Europe, Asia, and Rest of World (ROW)), is forecast to increase by USD 301.7 million. The market is expected to grow at a CAGR of   10.03% between 2024 and 2028.

• The autoimmune hemolytic anemia (AIHA) therapeutics market is experiencing a significant need for innovative treatment solutions due to the limited effectiveness and potential severe side effects of current options. Primary warm-type AIHA is predominantly treated through immunosuppression, typically with corticosteroids like prednisone. However, many patients fail to respond adequately, and prolonged, uncontrolled immunosuppression can lead to serious complications. Monoclonal antibodies, a newer therapeutic approach, have shown inconsistent results. Therefore, the development of targeted therapies for AIHA is crucial. Currently, corticosteroids, such as prednisone, remain the first-line treatment, with an initial dose of 1.0-1.5 mg/kg/day administered for 1-3 weeks. The therapeutic response typically occurs during the second week.
• The Autoimmune Hemolytic Anemia (AIHA) Therapeutics market represents a significant business opportunity due to the increasing prevalence of this autoimmune disorder. Key players in this market are developing innovative solutions to address the unmet medical needs of AIHA patients. These include immunosuppressive therapies, intravenous immunoglobulins, and corticosteroids. The market is expected to grow steadily, driven by rising awareness, advances in diagnostics, and the development of novel therapeutic approaches.

Access the full report to know who are the other key countries segment-wise forecast and historic data

Some of the Key Companies:

• AstraZeneca Plc
• Amneal Pharmaceuticals Inc.
• ANI Pharmaceuticals Inc.
• Apellis Pharmaceuticals Inc.
• argenx SE
• Baxter International Inc.
• Cipla Inc.
• Concord Biotech Ltd.
• F. Hoffmann La Roche Ltd.
• Hikma Pharmaceuticals Plc
• Incyte Corp.
• Kezar Life Sciences Inc.
• Nichi Iko Pharmaceutical Co. Ltd.
• Rigel Pharmaceuticals Inc.
• Sanofi SA
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/